Literature DB >> 19501262

HIV endocytosis after dendritic cell to T cell viral transfer leads to productive virus infection.

Imma Clotet-Codina1, Berta Bosch, Jordi Senserrich, María Teresa Fernández-Figueras, Ruth Peña, Ester Ballana, Margarita Bofill, Bonaventura Clotet, José A Esté.   

Abstract

Contacts between HIV-producing T cells and primary CD4+ T cells may induce the uptake of HIV by target cells that are endocytosed into trypsin-resistant compartments. We have now compared the mechanism of virus transmission from T cell-to-T cell versus infected dendritic cells (DCs)-to-T cell. In cocultures of HIV-1-infected DCs with primary CD4+ T cells, virus transmission to the target cells was resistant to trypsin treatment and could only be prevented by the anti-SUgp120 antibody IgGb12 but not by TAK-779, C34 or AZT. Importantly, upon stimulation of purified HIV-1-loaded CD4+ T cells with PHA/IL-2, cells became productively infected as measured by intracellular CAp24 staining and antigen determination in the cell supernatant. These results suggest that the viral endocytic transfer may represent a escape mechanism in the presence of drugs targeting HIV-1 entry or the host immune system.

Entities:  

Mesh:

Year:  2009        PMID: 19501262     DOI: 10.1016/j.antiviral.2009.03.009

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  21 in total

1.  In vitro activities of candidate microbicides against cell-associated HIV.

Authors:  Philippe Selhorst; Katrijn Grupping; Thomas Bourlet; Olivier Delézay; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

2.  ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.

Authors:  Emmanuel González-Ortega; Maria-Pau Mena; Marc Permanyer; Ester Ballana; Bonaventura Clotet; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

3.  Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites.

Authors:  Bin Yu; Dora P A J Fonseca; Sara M O'Rourke; Phillip W Berman
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

4.  Distinct requirements for HIV-cell fusion and HIV-mediated cell-cell fusion.

Authors:  Naoyuki Kondo; Mariana Marin; Jeong Hwa Kim; Tanay M Desai; Gregory B Melikyan
Journal:  J Biol Chem       Date:  2015-01-14       Impact factor: 5.157

5.  Trans-infection but not infection from within endosomal compartments after cell-to-cell HIV-1 transfer to CD4+ T cells.

Authors:  Marc Permanyer; Ester Ballana; Roger Badia; Eduardo Pauls; Bonaventura Clotet; José A Esté
Journal:  J Biol Chem       Date:  2012-07-30       Impact factor: 5.157

6.  RNA-Associated Early-Stage Antiviral Factor Is a Major Component of Lv2 Restriction.

Authors:  Kelly M Marno; Eithne O'Sullivan; Christopher E Jones; Julieta Díaz-Delfín; Claire Pardieu; Richard D Sloan; Áine McKnight
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

7.  Antiretroviral agents effectively block HIV replication after cell-to-cell transfer.

Authors:  Marc Permanyer; Ester Ballana; Alba Ruiz; Roger Badia; Eva Riveira-Munoz; Encarna Gonzalo; Bonaventura Clotet; José A Esté
Journal:  J Virol       Date:  2012-06-13       Impact factor: 5.103

Review 8.  HIV entry: a game of hide-and-fuse?

Authors:  Gregory B Melikyan
Journal:  Curr Opin Virol       Date:  2013-11-01       Impact factor: 7.090

9.  On the steps of cell-to-cell HIV transmission between CD4 T cells.

Authors:  Isabel Puigdomènech; Marta Massanella; Cecilia Cabrera; Bonaventura Clotet; Julià Blanco
Journal:  Retrovirology       Date:  2009-10-13       Impact factor: 4.602

Review 10.  Cell-Free versus Cell-to-Cell Infection by Human Immunodeficiency Virus Type 1 and Human T-Lymphotropic Virus Type 1: Exploring the Link among Viral Source, Viral Trafficking, and Viral Replication.

Authors:  Hélène Dutartre; Mathieu Clavière; Chloé Journo; Renaud Mahieux
Journal:  J Virol       Date:  2016-08-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.